Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Circulating tumour cell detection ups risk of biochemical recurrence in prostate cancer

06 Jun 2020

Detection of circulating tumour cells appears to increase the risk of biochemical recurrence in patients with prostate cancer, suggesting that such detection precedes prostate-specific antigen (PSA) risk following surgery in cases of prostate cancer recurrence, reveals a recent study.

“Circulating tumour cells in the blood were frequently detected in patients with undetectable PSA levels after radical prostatectomy for localized prostate cancer,” the investigators said.

This study prospectively enrolled 203 patients with an undetectable PSA who had undergone radical prostatectomy for prostate cancer. Circulating tumour cell sampling was performed at a median of 4.5 months after surgery.

Biochemical recurrence-free survival was the primary endpoint. A novel approach with a replication-competent adenovirus controlled by PSA/prostate-specific membrane antigen transcription regulatory elements (Ad5/35E1aPSESE4) was used to detect circulating tumour cells in the blood of patients.

Seventy-three (36.0 percent) patients with undetectable PSA concentrations after surgery were found to have circulating tumour cells. Biochemical recurrence at 3 years from the time of surgery was significantly higher in patients with positive than negative circulating tumour cells (81.6 percent vs 48.9 percent; log rank p<0.001).

In multivariable analysis, postoperative circulating tumour cell detection independently correlated with a higher risk of biochemical recurrence (hazard ratio, 5.42, 95 percent confidence interval, 3.24–9.06; p<0.001). Additionally, C-index was increased in combinations of multivariable model and postoperative circulating tumour cell detection compared with the multivariable model alone.

“Large-scale validation is needed in the future,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.